-
A Recognized Practitioner
Jennifer has been recognized by Chambers USA and named a "Top Woman of Law" and a “Go-To Business Lawyer” by Massachusetts Lawyers Weekly.
-
Thought Leadership
She serves on the General Counsel Advisory Board of the National Venture Capital Association.
-
Focus on Cutting-Edge Life Science Companies
Jennifer helps a variety of start-ups and pre- and post-IPO companies in the pharmaceutical, biotechnology, medical device and diagnostic industries, combining her legal expertise with her background in Biology and Biological Engineering.
Jennifer Fang is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative start-ups grow into successful enterprises by providing counsel to the founders, management teams, and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is experienced in negotiating and executing a variety of corporate transactions, including conversions, spinouts, debt and equity financings, public offerings, PIPEs, mergers and acquisitions, and joint ventures. She also counsels venture capital, growth capital, and strategic investors with respect to their investment transactions and their existing portfolio companies. Her practice focuses on companies that can improve patient lives and healthcare through innovations and advances, including in gene editing, cell therapy, novel therapeutics, synthetic biology, proteomics, diagnostics, bioinformatics, medical devices, and research and manufacturing tools and processes.
Jennifer has been recognized by various publications and organizations for her work in the life sciences industry. Chambers USA notes she is increasing recognized for her work advising emerging life sciences companies on a wide range of corporate matters, including financings, IPOs, and M&A. Jennifer was also honored with the “Best Under 40” award by the National Asian Pacific American Bar Association (NAPABA), which highlighted her work with growing start-ups to enterprises, and named a “Top Woman of Law” and a "Go-To Business Lawyer" by Massachusetts Lawyers Weekly.
She is also a frequent speaker on corporate and securities topics, such as company formation risks, equity compensation issues, angel and venture financing terms, and founder pitfalls, and currently serves on the General Counsel Advisory Board of the National Venture Capital Association (NVCA) and is a member of the Advisory Board for the American Cancer Society (ACS) BrightEdge Entrepreneurs (BEE) program.
In her free time, she enjoys mentoring young lawyers, entrepreneurs, and investors in the local community.
Jennifer Fang is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative start-ups grow into successful enterprises by providing counsel to the founders, management teams, and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is experienced in negotiating and executing a variety of corporate transactions, including conversions, spinouts, debt and equity financings, public offerings, PIPEs, mergers and acquisitions, and joint ventures. She also counsels venture capital, growth capital, and strategic investors with respect to their investment transactions and their existing portfolio companies. Her practice focuses on companies that can improve patient lives and healthcare through innovations and advances, including in gene editing, cell therapy, novel therapeutics, synthetic biology, proteomics, diagnostics, bioinformatics, medical devices, and research and manufacturing tools and processes.
Jennifer has been recognized by various publications and organizations for her work in the life sciences industry. Chambers USA notes she is increasing recognized for her work advising emerging life sciences companies on a wide range of corporate matters, including financings, IPOs, and M&A. Jennifer was also honored with the “Best Under 40” award by the National Asian Pacific American Bar Association (NAPABA), which highlighted her work with growing start-ups to enterprises, and named a “Top Woman of Law” and a "Go-To Business Lawyer" by Massachusetts Lawyers Weekly.
She is also a frequent speaker on corporate and securities topics, such as company formation risks, equity compensation issues, angel and venture financing terms, and founder pitfalls, and currently serves on the General Counsel Advisory Board of the National Venture Capital Association (NVCA) and is a member of the Advisory Board for the American Cancer Society (ACS) BrightEdge Entrepreneurs (BEE) program.
In her free time, she enjoys mentoring young lawyers, entrepreneurs, and investors in the local community.
- J.D., University of Pennsylvania Law School, 2009
- M.Eng., Biological Engineering, Massachusetts Institute of Technology, 2006
- B.S., Biology, Massachusetts Institute of Technology, 2005
- Member, MIT Alumni Angels
- Member, MIT Alumni Life Science Angels
- Member, General Counsel Advisory Board, National Venture Capital Association
- Member, Marvin's Angels
- Member, Advisory Board, American Cancer Society (ACS) BrightEdge Entrepreneurs (BEE) program
- Steering Committee, Boston Bar Association, Women in Life Sciences
- Member, Breaking 7%
- Member, Business & Commercial Law Curriculum Advisory Committee, Massachusetts Continuing Legal Education
- Former Treasurer and Director, Asian American Lawyers Association of Massachusetts
- Recognized in the Massachusetts Life Sciences category in the 2023-2025 editions of Chambers USA: America’s Leading Lawyers for Business
- Honored as a 2022 “Best Under 40” award recipient by the NAPABA
- Named a “2022 Top Women of Law” honoree by Massachusetts Lawyers Weekly
- Named to Boston Magazine’s “Top Lawyers” list in 2021-2024
- State Bar of Massachusetts
- State Bar of New York
- J.D., University of Pennsylvania Law School, 2009
- M.Eng., Biological Engineering, Massachusetts Institute of Technology, 2006
- B.S., Biology, Massachusetts Institute of Technology, 2005
- Member, MIT Alumni Angels
- Member, MIT Alumni Life Science Angels
- Member, General Counsel Advisory Board, National Venture Capital Association
- Member, Marvin's Angels
- Member, Advisory Board, American Cancer Society (ACS) BrightEdge Entrepreneurs (BEE) program
- Steering Committee, Boston Bar Association, Women in Life Sciences
- Member, Breaking 7%
- Member, Business & Commercial Law Curriculum Advisory Committee, Massachusetts Continuing Legal Education
- Former Treasurer and Director, Asian American Lawyers Association of Massachusetts
- Recognized in the Massachusetts Life Sciences category in the 2023-2025 editions of Chambers USA: America’s Leading Lawyers for Business
- Honored as a 2022 “Best Under 40” award recipient by the NAPABA
- Named a “2022 Top Women of Law” honoree by Massachusetts Lawyers Weekly
- Named to Boston Magazine’s “Top Lawyers” list in 2021-2024
- State Bar of Massachusetts
- State Bar of New York
Select Public Offerings
- Arcellx in its $124 million initial public offering
- Arcellx in its $129 million follow-on public offering
- Ascentage Pharma in its $126 million U.S. initial public offering
- bluebird bio in its $116 million initial public offering*
- Denali Therapeutics in its $207 follow-on offering
- Eloqua in its $92 million initial public offering*
- Otonomy in its $60 million follow-on offering
- Otonomy in its $30 million follow-on offering
- Oyster Point Pharma in its $92 million initial public offering
- Pacific Biosciences in its $69 million follow-on offering
- Proteostasis Therapeutics in its $50 million initial public offering*
- SpyGlass Pharma in its $150 million initial public offering
- Tenaya Therapeutics in its $207 million initial public offering
- Tenaya Therapeutics in its $75 million follow-on offering
- Tranzyme Pharma in its $51 million initial public offering*
- Underwriters in the $90 million initial public offering of Everbridge*
- Underwriters in the $104 million initial public offering of Acacia Communications*
- Underwriters in the $185 million follow-on offering of Casa Systems
- Vital Therapies in its $40 million follow-on offering
Select Investor-Side Financings
- a16z in its investments in Pearl Health
- Boxer Capital in its investments in Black Diamond, Shoreline, Tango, and Vivace, among others
- F-Prime Capital in its investments in Atalanta and Zenflow, among others
- Novo Ventures in its investments in Disc Medicine, Praxis Precision Medicines, and Tempus, among others
- RA Capital in its investments in Acumen, AN2, Capacity Bio, Rivus, PepGen, Synthego, and Vivace, among others
- RTW Investments in its investments in Artios Pharma, Kyverna, Lycia, and Oricell, among others
- TPG Capital in its investment in Asklepios BioPharmaceutical (AskBio)
- Vida Ventures in its investment in Vigil Neuro
- Features Capital, Flagship, NEA, and United Therapeutics in a number of other investments
Select M&A Transactions
- LENZ Therapeutics in its reverse merger with Graphite Bio in an all-stock deal
- Tilos Therapeutics in its sale to Merck for up to $773 million
- Tranzyme Pharma in its sale to Ocera Therapeutics in an all-stock deal*
- Verve in its acquisition of JusTours and Campus Vacations
*Denotes experience at another firm prior to joining Wilson Sonsini
Select Public Offerings
- Arcellx in its $124 million initial public offering
- Arcellx in its $129 million follow-on public offering
- Ascentage Pharma in its $126 million U.S. initial public offering
- bluebird bio in its $116 million initial public offering*
- Denali Therapeutics in its $207 follow-on offering
- Eloqua in its $92 million initial public offering*
- Otonomy in its $60 million follow-on offering
- Otonomy in its $30 million follow-on offering
- Oyster Point Pharma in its $92 million initial public offering
- Pacific Biosciences in its $69 million follow-on offering
- Proteostasis Therapeutics in its $50 million initial public offering*
- SpyGlass Pharma in its $150 million initial public offering
- Tenaya Therapeutics in its $207 million initial public offering
- Tenaya Therapeutics in its $75 million follow-on offering
- Tranzyme Pharma in its $51 million initial public offering*
- Underwriters in the $90 million initial public offering of Everbridge*
- Underwriters in the $104 million initial public offering of Acacia Communications*
- Underwriters in the $185 million follow-on offering of Casa Systems
- Vital Therapies in its $40 million follow-on offering
Select Investor-Side Financings
- a16z in its investments in Pearl Health
- Boxer Capital in its investments in Black Diamond, Shoreline, Tango, and Vivace, among others
- F-Prime Capital in its investments in Atalanta and Zenflow, among others
- Novo Ventures in its investments in Disc Medicine, Praxis Precision Medicines, and Tempus, among others
- RA Capital in its investments in Acumen, AN2, Capacity Bio, Rivus, PepGen, Synthego, and Vivace, among others
- RTW Investments in its investments in Artios Pharma, Kyverna, Lycia, and Oricell, among others
- TPG Capital in its investment in Asklepios BioPharmaceutical (AskBio)
- Vida Ventures in its investment in Vigil Neuro
- Features Capital, Flagship, NEA, and United Therapeutics in a number of other investments
Select M&A Transactions
- LENZ Therapeutics in its reverse merger with Graphite Bio in an all-stock deal
- Tilos Therapeutics in its sale to Merck for up to $773 million
- Tranzyme Pharma in its sale to Ocera Therapeutics in an all-stock deal*
- Verve in its acquisition of JusTours and Campus Vacations
*Denotes experience at another firm prior to joining Wilson Sonsini
Select Speaking Engagements
- Co-creator and host, “NextGen VC Podcast,” 2023-Present
- Judge, Pitch Competition, Northern New England MedTech Conference, November 12, 2024
- Panelist, "Breaking Down Barriers: Fostering Innovation in Healthcare," BrightEdge Converge on Cancer Summit Meeting, October 29, 2024
- Moderator, Venture Capital Financing Trends, Wilson Sonsini Biotech Conference, October 10, 2024
- Moderator, "Handling Hurdle: Case Studies and Perspectives from Life Sciences Investors and Partners," Biotech Investor Day, MIT Engine, September 10, 2024
- Judge, MIT Chinese Alumni Group Entrepreneur Bootcamp, May 3, 2024
- Speaker and Panelist, "Funding and Tech Strategies for Novel Therapeutic Modalities," Annual Forum on IP, March 21, 2024
- Speaker and Panelist, NVCA Financing Documents, Boston Bar Association, February 28, 2024
- Speaker and Panelist, Startup Financing: Understanding NVCA Financing Documents, 2023 AUTM Annual Meeting, February 20, 2023
- Panelist, Startup Business Development Course, 2023 AUTM Annual Meeting, February 19, 2023
- Panelist, Founders’ Agreements, Contracts and Foundations, MIT Sloan Entrepreneurial Founding & Teams course, February 16, 2023
Select Speaking Engagements
- Co-creator and host, “NextGen VC Podcast,” 2023-Present
- Judge, Pitch Competition, Northern New England MedTech Conference, November 12, 2024
- Panelist, "Breaking Down Barriers: Fostering Innovation in Healthcare," BrightEdge Converge on Cancer Summit Meeting, October 29, 2024
- Moderator, Venture Capital Financing Trends, Wilson Sonsini Biotech Conference, October 10, 2024
- Moderator, "Handling Hurdle: Case Studies and Perspectives from Life Sciences Investors and Partners," Biotech Investor Day, MIT Engine, September 10, 2024
- Judge, MIT Chinese Alumni Group Entrepreneur Bootcamp, May 3, 2024
- Speaker and Panelist, "Funding and Tech Strategies for Novel Therapeutic Modalities," Annual Forum on IP, March 21, 2024
- Speaker and Panelist, NVCA Financing Documents, Boston Bar Association, February 28, 2024
- Speaker and Panelist, Startup Financing: Understanding NVCA Financing Documents, 2023 AUTM Annual Meeting, February 20, 2023
- Panelist, Startup Business Development Course, 2023 AUTM Annual Meeting, February 19, 2023
- Panelist, Founders’ Agreements, Contracts and Foundations, MIT Sloan Entrepreneurial Founding & Teams course, February 16, 2023
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
- Privacy Policy
- Terms of Use
- Accessibility